Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of ORKA-001 in moderate-to-severe plaque psoriasis (EVERLAST-B)
2025-523797-17-00Phase 2Authorised
- Sponsor
- Oruka Therapeutics
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing ORKA-001 dose-ranging arm with Placebo arm (2 arms). Primary endpoint: Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16. Planned start May 2026; status: authorised.
02
Drugs
orka-001
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2025-523797-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523797-17-00.